A Case of Myeloid Sarcoma following Allogeneic HSCT Presenting as Localized Hip Pain

Zhang, Shannon; Charlton, C. F.; Amaraneni, Akshay; Maher, Keri Renee

doi:10.1155/2019/2674359

Cited by 3 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A case of MS following allogeneic stem cell transplantation was introduced by Zhang et al, which was characterized by localized pelvic pain. 21 In another study, a case of a 47-year-old woman with MS of the vulva was reported who presented with symptoms of AML. 22 Also, Wang et al described a case of MS of the small bowel, kidney, and mesenteric lymph nodes in a 26-year-old male patient who suffered from intermittent upper abdominal pain.…”

Section: Discussionmentioning

confidence: 98%

Incidence of Hematopoietic Sarcoma in Iranian Population

et al. 2021

View full text Add to dashboard Cite

Background: The heterogeneous nature of hematopoietic sarcoma has restricted the diagnosis and treatment of this disease to the extent that annually, several patients lose their lives. Given the lack of comprehensive epidemiologic information on the incidence of hematopoietic sarcoma in the Iranian population, we designed the present study to evaluate the distribution pattern of this disease. Methods: In this national population-based cancer registry study, we collected data from patients diagnosed with hematopoietic sarcoma who were registered in the Iran National Cancer Registry (INCR) between 2009 and 2013. For each patient, the variables of age, sex, province, year of diagnosis, site of involvement and morphology were collected. Results: In 45 cases from 18 provinces of Iran, we found that the incidence rate of the disease was 0.60 (95% CI: 0.44-0.80) per million persons. Among all provinces, Ilam had the highest incidence of hematopoietic sarcoma with a rate of 2 (95% CI: 0.05-11.14) per million persons, while Isfahan had the lowest incidence with a rate of 0.21 (95% CI: 0.01-1.16) per million persons. The incidence rate of the disease increased with age and the disease was slightly more common in men (0.63 [95% CI: 0.41-0.94] vs. 0.56 [95% CI: 0.35-0.86] per million persons). The frequency of hematopoietic sarcoma in connective and soft tissues was higher than other anatomical sites and we found that myeloid morphology was the most prevalent morphology. Conclusion:The resulting data provided a valuable perspective on the distribution pattern of hematopoietic sarcoma in Iran; however, further studies are required to confirm these results.

show abstract

Section: Discussionmentioning

confidence: 98%

Incidence of Hematopoietic Sarcoma in Iranian Population

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Zhang et al. also reported a patient with MDS and complex karyotype, who underwent a reduced intensity MUD, but relapsed as myeloid sarcoma two years later, as a pelvic mass without bone marrow involvement [13] . In this paper, we report the first case in which a MDS patient relapsed post-transplant as myeloid sarcoma involving the gastrointestinal tract.…”

Section: Discussionmentioning

confidence: 99%

“…Myeloid sarcoma can involve any part of the body, including skin, CNS, soft tissue, bone, lymph node, and rarely, the breast, eye, heart, and nerves [8] . Myeloid sarcoma may occur due to dysfunctional homing signals for blasts [ [8] , [9] , [10] , 13 ]. It is believed that post-transplant myeloid sarcomas develop secondary to the ability of myeloblasts in extra-medullary sites to evade immune surveillance [18] .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Post-transplant relapse of therapy-related MDS as gastric myeloid sarcoma: Case report and review of literature

Song

Ghayouri

Hiya

et al. 2021

Leukemia Research Reports

View full text Add to dashboard Cite

Introduction Myelodysplastic syndrome (MDS) are hematologic neoplasms characterized by morphologic dysplasia and ineffective hematopoiesis in the bone marrow. The only potentially curative therapy is stem cell transplant. However, relapse remains a major challenge and is seen in about 25–40% of cases. Myeloid sarcoma presenting as relapse post allogeneic transplant for myeloid neoplasms is rare. We report the sentinel case of a patient with MDS who relapsed as gastric myeloid sarcoma 1 ½ years after allogeneic stem cell transplant. Case Presentation Sixty-nine-year-old male who was diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in 2006 and transitional cell bladder carcinoma in 2008. In 2011, he developed therapy-related myeloid neoplasm t(7;22) and no excess blasts. He was treated with Vidaza followed by a MUD hematopoietic stem cell transplant on 8/24/2012. In 2013 the patient developed anorexia and gastric biopsies showed severe gastritis. Repeat gastric biopsy on 02/05/2014 showed an extensive mononuclear infiltrate which could easily be confused with lymphocytes but staining showed myeloid sarcoma. Marrow was negative. The patient remained refractory to therapy and expired 08/10/2016. Conclusion In summary, we report the first case of GI relapse of MDS as a myeloid sarcoma post-transplant. We seek to alert our audience of this potentially serious diagnostic pitfall, particularly one that can be relatively easily resolved on the basis of immunohistochemical profiling.

show abstract

Insights into the role of intestinal microbiota in hematopoietic stem-cell transplantation

Zama

Bossù

Leardini

et al. 2020

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

The gut microbiota (GM) is able to modulate the human immune system. The development of novel investigation methods has provided better characterization of the GM, increasing our knowledge of the role of GM in the context of hematopoietic stem-cell transplantation (HSCT). In particular, the GM influences the development of the major complications seen after HSCT, having an impact on overall survival. In fact, this evidence highlights the possible therapeutic implications of modulation of the GM during HSCT. Insights into the complex mechanisms and functions of the GM are essential for the rational design of these therapeutics. To date, preemptive and curative approaches have been tested. The current state of understanding of the impact of the GM on HSCT, and therapies targeting the GM balance is reviewed herein.

show abstract

A Case of Myeloid Sarcoma following Allogeneic HSCT Presenting as Localized Hip Pain

Cited by 3 publications

References 7 publications

Incidence of Hematopoietic Sarcoma in Iranian Population

Incidence of Hematopoietic Sarcoma in Iranian Population

Post-transplant relapse of therapy-related MDS as gastric myeloid sarcoma: Case report and review of literature

Insights into the role of intestinal microbiota in hematopoietic stem-cell transplantation

Contact Info

Product

Resources

About